急性リンパ性白血病の世界市場

◆英語タイトル:Acute Lymphoblastic Leukemia Market (Type - B-cell, T-cell; Treatment - Chemotherapy, Radiation Therapy, Bone Marrow Transplant, Targeted Therapy, Immunotherapy; End user - Hospital, Clinics) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026
◆商品コード:TPM-C03051
◆発行会社(リサーチ会社):Transparency Market Research
◆発行日:2019年1月
◆ページ数:184
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,795 ⇒換算¥637,450見積依頼/購入/質問フォーム
Multi UserUSD8,795 ⇒換算¥967,450見積依頼/購入/質問フォーム
Global Site LicenseUSD11,795 ⇒換算¥1,297,450見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTransparency Market Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Transparency Market Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Transparency Market Researchが調査・発行した当レポートは、急性リンパ性白血病の世界市場について調べ、急性リンパ性白血病の世界規模、市場動向、市場環境、タイプ別(B細胞、T細胞)分析、治療法別(化学療法、放射線治療、骨髄移植、標的療法、免疫療法)分析、エンドユーザー別(病院、診療所)分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめました。
・序文・調査範囲・調査手法
・エグゼクティブサマリー
・急性リンパ性白血病の世界市場動向
・急性リンパ性白血病の世界市場環境
・急性リンパ性白血病の世界市場規模
・急性リンパ性白血病の世界市場規模:タイプ別(B細胞、T細胞)
・急性リンパ性白血病の世界市場規模:治療法別(化学療法、放射線治療、骨髄移植、標的療法、免疫療法)
・急性リンパ性白血病の世界市場規模:エンドユーザー別(病院、診療所)
・急性リンパ性白血病の世界市場:地域別市場規模・分析
・急性リンパ性白血病の北米市場規模・予測
・急性リンパ性白血病のアメリカ市場規模・予測
・急性リンパ性白血病の中南米市場規模・予測
・急性リンパ性白血病のヨーロッパ市場規模・予測
・急性リンパ性白血病のアジア市場規模・予測
・急性リンパ性白血病の日本市場規模・予測
・急性リンパ性白血病の中国市場規模・予測
・急性リンパ性白血病のインド市場規模・予測
・急性リンパ性白血病の中東市場規模・予測
・急性リンパ性白血病のアフリカ市場規模・予測
・競争状況・関連企業情報
【レポートの概要】

Global Acute Lymphoblastic Leukemia Market: Overview

This report analyzes the current and future scenario of the global acute lymphoblastic leukemia market. Increase in patient population with acute lymphoblastic leukemia, expansion of the pharmaceutical industry, improvement in health care infrastructure, and increase in the number of clinical trials are projected to be major drivers of the global market during the forecast period.

The global acute lymphoblastic leukemia market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on treatment, type, end-user, and region. A detailed qualitative analysis of drivers and restraints of the market, and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global acute lymphoblastic leukemia market.

Global Acute Lymphoblastic Leukemia Market: Key Segments

In terms of type, the global acute lymphoblastic leukemia market has been classified into B-cell and T-cell. Based on treatment, the global acute lymphoblastic leukemia market has been segregated into chemotherapy, radiation therapy, bone marrow transplant, targeted therapy, and immunotherapy. The segments have been analyzed based on available drug product used during the treatment of acute lymphoblastic leukemia, cost-effectiveness, and preference for industries. In terms of end-user, the global market has been divided into hospitals, clinics, and others. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Global Acute Lymphoblastic Leukemia Market: Regional Outlook

In terms of region, the global acute lymphoblastic leukemia market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, Israel, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles major players in the global acute lymphoblastic leukemia market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players profiled in the market report include Sanofi, Pfizer, Novartis AG, F. Hoffmann-La Roche Ltd., Erytech Pharma Inc., Celgene Corporation, Amgen, Inc. Bristol-Myers Squibb Company, and Spectrum Pharmaceuticals, Inc.

The global acute lymphoblastic leukemia market has been segmented as below:

Global Acute Lymphoblastic Leukemia Market, by Type
B-cell
T-cell
Global Acute Lymphoblastic Leukemia Market, by Treatment
Chemotherapy
Radiation Therapy
Bone Marrow Transplant
Targeted Therapy
Immunotherapy
Global Acute Lymphoblastic Leukemia Market, by End-user
Hospitals
Clinics
Others
Global Acute Lymphoblastic Leukemia Market, by Region
North America
U.S.
Canada
Europe
Germany
U.K.
Italy
France
Spain
Rest of Europe
Asia Pacific
India
China
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Israel
Rest of Middle East & Africa

【レポートの目次】

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights

2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology

3. Executive Summary

4. Market Overview
4.1. Introduction
4.2. Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, 2016–2026
4.3. Global Acute Lymphoblastic Leukemia Market Outlook
4.4. Key Industry Developments

5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
5.3. Restraints
5.4. Opportunities
5.5. Key Trends

6. Global Acute Lymphoblastic Leukemia Market, by Type
6.1. Introduction
6.2. Global Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Type
6.3. Global Acute Lymphoblastic Leukemia Market Value Forecast, by Type
6.4. Global Acute Lymphoblastic Leukemia Market Analysis, by Type
6.4.1. B-cell
6.4.2. T-cell

7. Global Acute Lymphoblastic Leukemia Market, by Treatment
7.1. Key Findings
7.2. Introduction
7.3. Global Acute Lymphoblastic Leukemia Market Value Share Analysis, by Treatment
7.4. Global Acute Lymphoblastic Leukemia Market Forecast, Treatment
7.5. Global Acute Lymphoblastic Leukemia Market Analysis, by Treatment
7.5.1. Chemotherapy
7.5.2. Radiation Therapy
7.5.3. Bone Marrow Transplant
7.5.4. Targeted Therapy
7.5.5. Immunotherapy
7.6. Global Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Treatment

8. Global Acute Lymphoblastic Leukemia Market, by End-user
8.1. Key Findings
8.2. Introduction
8.3. Global Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
8.4. Global Acute Lymphoblastic Leukemia Market Forecast, by End-user
8.5. Global Acute Lymphoblastic Leukemia Market Analysis, by End-user
8.5.1. Hospitals
8.5.2. Clinics
8.5.3. Others
8.6. Global Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user

9. Acute Lymphoblastic Leukemia Market Analysis, by Region
9.1. Key Findings
9.2. Global Market Scenario
9.3. Global Acute Lymphoblastic Leukemia Market Value Share Analysis, by Region
9.4. Global Acute Lymphoblastic Leukemia Market Forecast, by Region
9.4.1. North America
9.4.2. Europe
9.4.3. Asia Pacific
9.4.4. Latin America
9.4.5. Middle East & Africa
9.5. Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Region

10. North America Acute Lymphoblastic Leukemia Market
10.1. Key Findings
10.2. North America Acute Lymphoblastic Leukemia Market Overview
10.3. North America Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country
10.4. North America Acute Lymphoblastic Leukemia Market Value Forecast, by Country
10.4.1. U.S.
10.4.2. Canada
10.5. North America Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Type
10.6. North America Acute Lymphoblastic Leukemia Market Value Forecast, by Type
10.6.1. B-cell
10.6.2. T-cell
10.7. North America Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
10.8. North America Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
10.8.1. Chemotherapy
10.8.2. Radiation Therapy
10.8.3. Bone Marrow Transplant
10.8.4. Targeted Therapy
10.8.5. Immunotherapy
10.9. North America Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
10.10. North America Acute Lymphoblastic Leukemia Market Forecast, End-user
10.10.1. Hospitals
10.10.2. Clinics
10.10.3. Others
10.11. North America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user

11. Europe Acute Lymphoblastic Leukemia Market
11.1. Key Findings
11.2. Europe Acute Lymphoblastic Leukemia Market Overview
11.3. Europe Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.4. Europe Acute Lymphoblastic Leukemia Market Value Forecast, by Country/Sub-region
11.4.1. Germany
11.4.2. U.K.
11.4.3. France
11.4.4. Spain
11.4.5. Italy
11.4.6. Rest of Europe
11.5. Europe Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Type
11.6. Europe Acute Lymphoblastic Leukemia Market Value Forecast, by Type
11.6.1. B-cell
11.6.2. T-cell
11.7. Europe Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
11.8. Europe Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
11.8.1. Chemotherapy
11.8.2. Radiation Therapy
11.8.3. Bone Marrow Transplant
11.8.4. Targeted Therapy
11.8.5. Immunotherapy
11.9. Europe Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
11.10. Europe Acute Lymphoblastic Leukemia Market Forecast, End-user
11.10.1. Hospitals
11.10.2. Clinics
11.10.3. Others
11.11. Europe Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user

12. Asia Pacific Acute Lymphoblastic Leukemia Market
12.1. Key Findings
12.2. Asia Pacific Acute Lymphoblastic Leukemia Market Overview
12.3. Asia Pacific Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.4. Asia Pacific Acute Lymphoblastic Leukemia Market Value Forecast, by Country/Sub-region
12.4.1. China
12.4.2. Japan
12.4.3. India
12.4.4. Australia & New Zealand
12.4.5. Rest of Asia Pacific
12.5. Asia Pacific Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Type
12.6. Asia Pacific Acute Lymphoblastic Leukemia Market Value Forecast, by Type
12.6.1. B-cell
12.6.2. T-cell
12.7. Asia Pacific Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
12.8. Asia Pacific Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
12.8.1. Chemotherapy
12.8.2. Radiation Therapy
12.8.3. Bone Marrow Transplant
12.8.4. Targeted Therapy
12.8.5. Immunotherapy
12.9. Asia Pacific Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
12.10. Asia Pacific Acute Lymphoblastic Leukemia Market Forecast, End-user
12.10.1. Hospitals
12.10.2. Clinics
12.10.3. Others
12.11. Asia Pacific Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user

13. Latin America Acute Lymphoblastic Leukemia Market
13.1. Key Findings
13.2. Latin America Acute Lymphoblastic Leukemia Market Overview
13.3. Latin America Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.4. Latin America Acute Lymphoblastic Leukemia Market Value Forecast, by Country/Sub-region
13.4.1. Brazil
13.4.2. Mexico
13.4.3. Rest of Latin America
13.5. Latin America Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Type
13.6. Latin America Acute Lymphoblastic Leukemia Market Value Forecast, by Type
13.6.1. B-cell
13.6.2. T-cell
13.7. Latin America Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
13.8. Latin America Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
13.8.1. Chemotherapy
13.8.2. Radiation Therapy
13.8.3. Bone Marrow Transplant
13.8.4. Targeted Therapy
13.8.5. Immunotherapy
13.9. Latin America Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
13.10. Latin America Acute Lymphoblastic Leukemia Market Forecast, End-user
13.10.1. Hospitals
13.10.2. Clinics
13.10.3. Others
13.11. Latin America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user

14. Middle East & Africa Acute Lymphoblastic Leukemia Market
14.1. Key Findings
14.2. Middle East & Africa Acute Lymphoblastic Leukemia Market Overview
14.3. Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Country/Sub-region
14.4. Middle East & Africa Acute Lymphoblastic Leukemia Market Value Forecast, by Country
14.4.1. GCC Countries
14.4.2. Israel
14.4.3. South Africa
14.4.4. Rest of Middle East & Africa
14.5. Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Type
14.6. Middle East & Africa Acute Lymphoblastic Leukemia Market Value Forecast, by Type
14.6.1. B-cell
14.6.2. T-cell
14.7. Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share and Attractiveness Analysis, by Treatment
14.8. Middle East & Africa Acute Lymphoblastic Leukemia Market Value Forecast, by Treatment
14.8.1. Chemotherapy
14.8.2. Radiation Therapy
14.8.3. Bone Marrow Transplant
14.8.4. Targeted Therapy
14.8.5. Immunotherapy
14.9. Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user
14.10. Middle East & Africa Acute Lymphoblastic Leukemia Market Forecast, End-user
14.11. Hospitals
14.12. Clinics
14.13. Others
14.14. Middle East & Africa Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user

15. Competition Landscape
15.1. Acute Lymphoblastic Leukemia Market Share Analysis, by Company
15.2. Competition Matrix
15.3. Company Profile
15.3.1. Pfizer, Inc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Novartis AG
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. F. Hoffmann-La Roche Ltd.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Sanofi
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Erytech Pharma Inc.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. CELGENE CORPORATION
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Amgen, Inc.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Bristol-Myers Squibb Company
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Spectrum Pharmaceuticals, Inc.
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview

List of Tables

Table 01: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Type, 2016–2026
Table 02: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016 – 2026
Table 03: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user, 2016–2026
Table 04: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 05: North America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country,
Table 06: North America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Type,
Table 07: North America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016–2026
Table 08: North America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user, 2016 – 2026
Table 09: Europe Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country/Sub-region,
Table 10: Europe Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Type,
Table 11: Europe Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016–2026
Table 12: Europe Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user, 2016 – 2026
Table 13: Asia Pacific Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 14: Asia Pacific Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Type,
Table 15: Asia Pacific Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016–2026
Table 16: Asia Pacific Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user, 2016 – 2026
Table 17: Latin America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country/Sub-region,
Table 18: Latin America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Type,
Table 19: Latin America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016–2026
Table 20: Latin America Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user, 2016 – 2026
Table 21: Middle East & Africa Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 22: Middle East & Africa Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Type,
Table 23: Middle East & Africa Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by Treatment, 2016–2026
Table 24: Middle East & Africa Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, by End-user,

List of Figures

Figure 01: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, 2016–2026
Figure 02: Global Acute Lymphoblastic Leukemia Market Value Share (%), by Type (2017)
Figure 03: Global Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment (2017)
Figure 04: Global Acute Lymphoblastic Leukemia Market Value Share (%), by End-user (2017)
Figure 05: Global Acute Lymphoblastic Leukemia Market Value Share (%), by Region (2017)
Figure 06: Global Acute Lymphoblastic Leukemia Market Value Share (%), by Type, 2018 and 2026
Figure 07: Global Acute Lymphoblastic Leukemia Market Attractiveness, by Type, 2018–2026
Figure 08: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by B-cell
Figure 09: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by T-cell
Figure 10: Global Acute Lymphoblastic Leukemia Market Value Share Analysis, by Treatment, 2018-2026
Figure 11: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Chemotherapy
Figure 12: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Radiation Therapy, 2016–2026
Figure 13: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Bone Marrow Transplant
Figure 14: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Targeted Therapy, 2016–2026
Figure 15: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Immunotherapy, 2016–2026
Figure 16: Global Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Treatment, 2018-2026
Figure 17: Global Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
Figure 18: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospitals
Figure 19: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Clinics, 2016–2026
Figure 20: Global Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2026
Figure 21: Global Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018–2026
Figure 22: Global Acute Lymphoblastic Leukemia Market Value Share Analysis, by Region, 2018 and 2026
Figure 23: Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Region, 2018-2026
Figure 24: North America Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 25: North America Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country, 2018 and 2026
Figure 26: North America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country, 2018–2026
Figure 27: North America Acute Lymphoblastic Leukemia Market Value Share Analysis, by Type, 2018 and 2026
Figure 28: North America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Type, 2018–2026
Figure 29: North America Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
Figure 30: North America Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
Figure 31: North America Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
Figure 32: North America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018-2026
Figure 33: Europe Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 34: Europe Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 35: Europe Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 36: Europe Acute Lymphoblastic Leukemia Market Value Share Analysis, by Type, 2018 and 2026
Figure 37: Europe Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Type, 2018–2026
Figure 38: Europe Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
Figure 39: Europe Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
Figure 40: Europe Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
Figure 41: Europe Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018-2026
Figure 42: Asia Pacific Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 43: Asia Pacific Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 44: Asia Pacific Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 45: Asia Pacific Acute Lymphoblastic Leukemia Market Value Share Analysis, by Type, 2018 and 2026
Figure 46: Asia Pacific Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Type, 2018–2026
Figure 47: Asia Pacific Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
Figure 48: Asia Pacific Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
Figure 49: Asia Pacific Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
Figure 50: Asia Pacific Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018-2026
Figure 51: Latin America Acute Lymphoblastic Leukemia Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
Figure 52: Latin America Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 53: Latin America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 54: Latin America Acute Lymphoblastic Leukemia Market Value Share Analysis, by Type, 2018 and 2026
Figure 55: Latin America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Type, 2018–2026
Figure 56: Latin America Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
Figure 57: Latin America Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
Figure 58: Latin America Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
Figure 59: Latin America Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018-2026
Figure 60: Middle East & Africa Acute Lymphoblastic Leukemia Market Value (US$ Mn) Forecast, 2016–2026
Figure 61: Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
Figure 62: Middle East & Africa Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
Figure 63: Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share Analysis, by Type, 2018 and 2026
Figure 64: Middle East & Africa Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by Type, 2018–2026
Figure 65: Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share (%), by Treatment, 2018 and 2026
Figure 66: Middle East & Africa Acute Lymphoblastic Leukemia Market Attractiveness, by Treatment, 2018–2026
Figure 67: Middle East & Africa Acute Lymphoblastic Leukemia Market Value Share Analysis, by End-user, 2018 and 2026
Figure 68: Middle East & Africa Acute Lymphoblastic Leukemia Market Attractiveness Analysis, by End-user, 2018–2026
Figure 69: Global Acute Lymphoblastic Leukemia Market Share, by Company, 2017
Figure 70: Pfizer, Inc.’s Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
Figure 71: Pfizer, Inc.’s Oncology Business Segment Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2017
Figure 72: Pfizer, Inc.’s Revenue Share (%), by Business Segment, 2017
Figure 73: Pfizer, Inc.’s Revenue Share (%), by Region, 2017
Figure 74: Novartis AG’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
Figure 75: Novartis AG’s Oncology Business Segment Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2017
Figure 76: Novartis AG’s Net Sales (%), by Business Segment, 2017
Figure 77: Novartis AG’s Net Sales (%), by Region, 2017
Figure 78: F. Hoffmann-La Roche Ltd.’s, Oncology Segment, Revenue (US$ Bn), 2015–2017
Figure 79: F. Hoffmann-La Roche Ltd.’s Pharmaceutical Segment R&D Expenditure (US$ Bn), 2015–2017
Figure 80: F. Hoffmann-La Roche Ltd.’s Pharmaceutical Segment Revenue (%), by Specialty (2017)
Figure 81: F. Hoffmann-La Roche Ltd.’s Pharmaceutical Segment Revenue (%), by Region (2017)
Figure 82: Sanofi’s Revenue (US$ Bn), 2014?2017
Figure 83: Sanofi’s Regional Sales Breakdown (%), 2017
Figure 84: CELGENE CORPORATION Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 85: CELGENE CORPORATION Marketing & Sales and R&D Expenses (%), 2015–2017
Figure 86: CELGENE CORPORATION Breakdown of Net Sales (%), by Business Segment, 2017
Figure 87: CELGENE CORPORATION Breakdown of Net Sales (%), by Region, 2017
Figure 88: Amgen, Inc. Marketing & Sales and R&D Expenses (%), 2015–2017
Figure 89: Amgen, Inc. Breakdown of Net Sales (%), by Region, 2017
Figure 90: Amgen, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 91: Bristol-Myers Squibb Company Revenue (US$ Bn), 2014-2017
Figure 92: Bristol-Myers Squibb Company R&D Expenditure (US$ Bn), 2015- 2017
Figure 93: Bristol-Myers Squibb Company Revenue, by Geography, 2017
Figure 94: Spectrum Pharmaceuticals, Inc. Revenue (US$ Mn), 2015- 2017
Figure 95: Spectrum Pharmaceuticals, Inc. R&D Expenditure (US$ Mn), 2014-2017

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[急性リンパ性白血病の世界市場]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆